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Abstract
Cerebrotendinous Xanthomatosis (CTX), a rare lipid storage disorder, is caused by recessive loss-of-function muta-
tions of the 27-sterol hydroxylase (CYP27A1), producing an alteration of the synthesis of bile acids, with an accumu-
lation of cholestanol. Clinical characteristics include juvenile cataracts, diarrhea, tendon xanthomas, cognitive
impairment and other neurological manifestations. Early diagnosis is critical, because treatment with cheno-
deoxycholic acid may prevent neurological damage. We studied the CYP27A1 gene in two Chilean CTX patients by
sequencing its nine exons, exon-intron boundaries, and cDNA from peripheral blood mononuclear cells. Patient 1 is
a compound heterozygote for the novel substitution c.256-1G > T that causes exon 2 skipping, leading to a prema-
ture stop codon in exon 3, and for the previously-known pathogenic mutation c.1183C > T (p.Arg395Cys). Patient 2 is
homozygous for the novel mutation c.1185-1G > A that causes exon 7 skipping and the generation of a premature
stop codon in exon 8, leading to the loss of the crucial adrenoxin binding domain of CYP27A1.
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Introduction
Cerebrotendinous xanthomatosis (CTX) [MIM
#213700] is an autosomal recessive disease caused by mu-
tations in the CYP27A1 gene, which encodes the mitochon-
drial enzyme 27-sterol hydroxylase (EC 1.14.13.15) in-
volved in bile acid synthesis. The primary bile acids cholic
acid (CA) and chenodeoxycholic acid (CDCA) are synthe-
sized by two complementary chemical pathways: the clas-
sic “neutral pathway”, considered as the main producer of
bile acids (approximately 50% CA and CDCA) and an al-
ternative “acidic pathway” leading to CDCA synthesis. The
27-sterol hydroxylase encoded by CYP27A1 catalyzes the
initial step in the acidic pathway, with the C27-hydroxy-
lation of cholesterol oxidation of the side chain sterol inter-
mediates in bile acid formation (Sundaram et al., 2008). As
a consequence of inherited genomic defects in CYP27A1,
there is an alteration of the production of bile acids, mainly
decreasing CDCA production. The immediate conse-
quence of this genetic defect is the compensatory increase
in the activity of the rate-limiting enzyme in the neutral bile
acid synthesis pathway, cholesterol 7-hydroxylase, lead-
ing to the accumulation of 7-hydroxylated bile acid pre-
cursors, in particular 7-hydroxy-4-cholesten-3-one. This
molecule is a precursor of cholestanol, which is elevated in
the plasma of CTX patients, as well as an increase in
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plasma cholestanol/cholesterol ratio (Björkhem and Hans-
son, 2010). Consequently, these molecules are abnormally
deposited in different tissues such as central nervous sys-
tem (CNS) and crystalline lens (Khan et al., 2013).
CTX diagnosis is based on clinical grounds. Re-
cently, an Italian group of experts in CTX has proposed a
suspicion index for early diagnosis (Mignarri et al., 2014).
Elevated levels of cholestanol levels in serum, high bile al-
cohol levels in urine and genetic testing, confirm the diag-
nosis. According to the literature, there is no established
genotype-phenotype correlation pattern in CTX. (Lee et al.,
2001).
At early stages of CTX, symptoms are childhood di-
arrhea and bilateral cataracts, which are usually diagnosed
during the first or second decade of life (Cenedella, 1996;
Moghadasian et al., 2002; Pilo-de-la-Fuente et al., 2011).
In more advanced stages, the disease is characterized by
tendom xanthomas as well as the presence of progressive
neurologic dysfunction signs that usually occur during the
second and the third decade of life. Less frequently, the
presence of seizures, coronary heart disease and early ath-
erosclerosis has been also described (Dotti et al., 2000).
Although the prevalence of the disease has been
roughly estimated in 1/50,000 (Salen et al., 1983), this fig-
ure varies by ethnicity and geographic location. In popula-
tions of Sephardic Jews of Moroccan origin, a prevalence
of 1/108 has been described (Berginer and Abeliovich,
1981), while in Caucasian populations of the United States
of America, the estimated prevalence is approximately
3-5/100,000 (Lorincz et al., 2005). There are, so far, more
than 50 different CYP27A1 mutations published
(http://www.hgmd.org). In Chile, two CTX patients have
been previously reported (Filippi et al., 2009; Huijgen et
al., 2012). The aim of the present report is to describe the
genetic, molecular and clinical characteristics of two Chil-
ean CTX patients.
Subjects and Methods
Clinical description of patients
This study was approved by the Ethical Review
Board of the School of Medicine of the Pontificia
Universidad Católica de Chile. Written informed consent
was signed by patients and relatives.
Patient 1: female, 42 years old. No history of consan-
guinity. History of unexplained chronic diarrhea and bilat-
eral cataracts diagnosed at age of 5 and operated in child-
hood. Since age of 28 she developed paraparesis and
progressive difficulty to walk.Neurological examination in
that moment showedbilateral pyramidal syndrome, cere-
bellar syndrome and deep sensory deficit in lower extremi-
ties. Brain magnetic resonance imaging (MRI) showed
involutive signs incerebellar and bilateral frontal regions,
with white matter involvement bulb and cerebellum. An
electrophysiological study of the lower extremities showed
signs of chronic sensorymotorpolyneuropathy. Laboratory
tests showed negative results for HIV, HTLV-1, and
VDRL. Plasma B12 and folic acid levels were normal. Thy-
roid function was normal. The patient showed a normal
lipid profile,exceptfor slightly elevated high density lipo-
protein cholesterol (HDL-C) (74.6 mg/dL). At age of 31,
CTX was suspected, although without presenting typical
tendinous xanthomas. This patient showed a concentration
of 64 mol/L of plasma cholestanol reported from an exter-
nal laboratory (normal values: 2-12.6 mol/L). At the mo-
ment of recruitment for this study, the patient isprostra-
ted,with a severe spastic tetraparesis, flexor pattern of the
four limbs, severe dysphagia that required installation of a
percutaneous endoscopic gastrostomy. There is no clinical
data of her bone condition at the moment of diagnosis. Due
to her clinical condition, it was not possible to perform a
bone densitometry at the moment of the recruitment.
Patient 2: male, 17 years old. Patient was adopted at
age of 5 months and no data of his biological parents are
available. He was hypotonic at infancy, without feeding or
respiratory impairments. He had motor and developmental
delay, with independent walking after 2.5 years old and lan-
guage (phrases) after 2 years old. Mother refers frequent
stools (twice daily with low consistency by periods) since
toddler. Difficulties in visual acuity were noticed at the age
of 10 years. Miopic astigmatism and bilateral cataracts
were diagnosed at 13 years old. On neurologic examina-
tion, the following signs were evident: macrocephaly, dys-
morphic signs with mild facial hypomimia, distal
hypotrophy in lower limbs; xanthomas on Achilles tendons
(both) and one on left triceps tendon. He had speaking,
reading, writing and drawing difficulties and distal paresis
with hyperreflexia with no spasticity in lower limbs. Fine
hands tremor; difficulty in walking on heels and subtle in-
stability in turns were evident. Brain MRI revealed T2 sig-
nal abnormalities on cerebellar hemispheric white matter.
Thyroid function was normal. Bone densitometry showed
low bone mineral mass in both hips and normal spine val-
ues (Left femoral neck Z-score -3.3; right femoral neck
Z-score -3.2). Levels of 25(OH) vitamin D were
14.2 ng/mL (normal values: 20-60 ng/mL). Plasma choles-
tanol levels were analyzed in an external laboratory yield-
ing a result of 2.6 mg/dL (normal values 0.17  0.12 mg/dL,
for children 3-16 years), thus confirming the diagnosis.
Molecular and bioinformatic methods
Total DNA and RNA were extracted from peripheral
blood in EDTA tubes using Mini blood kits (Qiagen) and
Trizol (Ambion) respectively. Genomic DNA was ampli-
fied and sequenced (Macrogen, Korea) using primers de-
signed to amplify the 9 intron/exon boundaries, as well as
the 3’ UTR of the CYP271A1 gene (NG_007959.1). Primer
sequences and thermal profiles are available under request
from authors. RNA (NM_000784.3) was reverse tran-
scribed with random primers (Applied Biosystem).
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Genomic sequence variation was described according to
the guidelines of the Human Genome Variation Society
(Den Dunnen and Antonarakis, 2000).
To assess the possible impact of the amino acid sub-
stitution p.Arg395Cys on protein structure and function,
we used the Polyphen-2 and PROVEAN (v1.1) programs
(Adzhubei et al., 2010; Choi et al., 2012). The two novel
intronic mutations found in our patients (Table 1) disrupt
the canonical splicing 3’ acceptor site. Subsequently, we
used the Human Splicing finder (HSF) software (Desmet et
al., 2009), which predicts the effect of the splice affecting
variants with high accuracy based on position weight matri-
ces. Natural splice sites (5’and 3’), branch points and
exonic splice enhancers among others are assigned with
consensus values. A delta Consensus Value (CV) of the
splice sites strength > 10% is likely to have an impact on
splicing (Desmet et al., 2009). When mutations affecting
intron positions -1,-2, +1 or +2 occur, the probability of
exon skipping, the use of pseudo 3’ or 5’ splice sites, reten-
tion of the mutated intron or cryptic splice sites, among oth-
ers, is higher (Faustino and Cooper, 2003).
Results
We found three different mutations in the CYP27A1
gene, listed in Table 1. Patient 1 is a compound hetero-
zygote harboring the novel mutation c.256-1G > T and the
previously described missense mutation c.1183 C > T
(p.Arg395Cys), shown in Figure 1A. Patient 2 is homozy-
gous for the novel mutation c.1185-1G > A, shown in Fig-
ure 1B. We have registered the new CYP27A1 mutations in
the Leiden Open Variation Database with accession num-
bers as following c.256-1G > T: #
DB_ID:CYP27A1_00069, and c-1185-1G > A: #
DB_ID:CYP27A1_00068. The third mutation c.1183C > T
or p.Arg395Cys (patient 1) has accession number: #
DB_ID:CYP27A1_00004 (http://www.lovd.nl/3.0/home),
is shown in Figure 1A.
The analysis of the novel mutation c.256-1G > T on
the splicing process, using the HSF program, predicted that
the nucleotide T lowers the strength (CV -32.9%) of the
natural splicing acceptor 3’ site (AG > AT) and also seems
to swop the 3’ site to a 5’ donor site with a CV -14.0. This
would predict a highly plausible skipping of exon 2 (191
nucleotides long). This imprecise splicing may shift the
reading frame creating a new amino acid sequence of 30
residues containing a premature stop codon
(GRTPLVPAAPGSEPAVAEASGSSALYGCFQ*).
In order to demonstrate the effect of the mutations
found in patient 1, we reverse transcribed total RNA ex-
tracted from leukocytes of peripheral blood. The cDNA
was amplified and sequenced in two segments: exon 1 to 4,
and exon 5 to 9. The sequence was concordant with the
compound heterozygote genotype found in the genomic
DNA, as both mutations were present. The cDNA sequence
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of exon 1 to 4 of showed the extended haplotype sequence
containing the intronic mutation c.256-1G > T and the nor-
mal haplotype. The main peaks correspond to the nucleo-
tide sequence of exon 2, while the weak background peaks
of the sequence correspond to the nucleotide sequence of
exon 3 (Figure 1C). This result indicates that exon 2 is in-
correctly spliced and exon 1 is joined to exon 3 in the ex-
tended haplotype carrying the c.256-1G > T mutation.
Thus, we have demonstrated the existence of exon skip-
ping, which was previously predicted by the HSF program.
The mutation c.256-1G > T has been named as
p.Val86Glyfs30Ter (Table 1).
Patient 1 cDNA also carry the c.1183C > T
(p.Arg395Cys) variant, which is located in the cDNA se-
quence corresponding to a TGT codon, codifying for
cysteine, as shown in Figure 1D. The first two nucleotides
of this codon come from exon 6 and the third nucleotide co-
mes from exon 7, with the c.1183C > T mutation thus being
located in the penultimate site of exon 6. The cDNA se-
quence analysis showed that there is no splice defect de-
rived from this mutation, given that exon 6 is correctly
joined with exon 7. On the other hand, the c.1183C > T mu-
tation generates a change in the amino acid sequence
(p.Arg395Cys) previously known to be pathogenic. Ac-
cording to bioinformatics predictions, Polyphen-2 showed
that p.Arg395Cys was “probably damaging” with the high-
est score possible of 1.0 (range 0.0 to 1.0). The tridimen-
sional model of CYP27A1 (±A) shows that Arg395
interacts with Phe438 by pi-cationic interaction and is also
involved in h-bond interactions with the carboxyl group of
Glu392 and the main-chain nitrogen from Pro441 (Figure
2B upper panel).
We found the novel mutation c.1185-1G > A in the
“-1” site of intron 6 in homozygous state in patient 2 (Fig-
ure 1B). The analysis of this mutation using HSF software
showed a decrease in the strength of the 3’ splice site (CV
-30.7%) and MaxEnt revealed a CV of -119.7% in
strength variation. Both values can be considered strong ev-
idence to predict a splice defect. Following the same proce-
dure used in Patient 1, we reverse transcribed total RNA
and amplified and sequenced the cDNA from patient 2. The
cDNA sequence of exon 5 to exon 9 of CYP27A1 of patient
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Figure 1 - Genomic and cDNA sequences showing case 1 and case 2 mutations. A) Case 1 genomic sequence showing heterozygote mutations. Black ar-
rows point to mutated nucleotides. B) Case 2 genomic sequence. Homozygous mutation shown by arrow. C) cDNA sequence of case 1 (Exons 1-3). One
haplotype has the normal sequence of exon 1 joined to exon 2, while the second haplotype shows exon 1 incorrectly joined to exon 3 (small peaks)
(RefSeq NG_007959). D) cDNA sequence of case 1 showing exon 6 and 7 with the mutation at codon 395. E) cDNA sequence of case 2 showing the join
of exon 6 to exon 8, skipping exon 7.
2 shows that exon 6 is joined to exon 8 (Figure 1E), demon-
strating that the homozygous mutation did affect normal
splicing of exon 7. We expect that the mutated protein loses
136 amino acids of the original sequence and only pre-
serves sequence identity up to Arg395, after this position
there is a new sequence of 28 amino acids
(PSLCSATMWCPGTPLPSLSLKASSPTAG*), which fi-
nalizes with a premature stop codon, generating a predicted
truncated protein of 423 amino acids. The nomenclature for
this mutation is p.Leu396ProfsTer28 (Table 1).
Discussion
As a consequence of the metabolic impairments ob-
served in Cerebrotendinous xanthomatosis, it has been pro-
posed that the primary treatment of this disease would be
oral CDCA administration, which is reported to decrease
plasma cholestanol levels (Sundaram et al., 2008). Statins
may also produce a synergistic effect by lowering the cho-
lesterol pool and improving the clinical response (Watts et
al., 1996; Verrips et al., 1999; Federico and Dotti, 2003).
Patient 1 is a compound heterozygote for two
CYP27A1 variants: c.256-1G > T and the missense muta-
tion c.1183C > T (p.Arg395Cys). The c.256-1G > T muta-
tion has not been previously reported in other case series.
We show here molecular evidence based on cDNA analysis
that such a mutation leads to a splice defect, also supported
by bioinformatics analysis. In this context, the c.256-1G >
T mutation causes exon 2 skipping and a premature stop
codon in exon 3 (p.Val86Glyfs30Ter). The second muta-
tion found in patient 1 (c.1183C > T), alters the protein se-
quence (p.Arg395Cys). This mutation (also termed
p.Arg362Cys) is the most common mutation found in CTX
patients of Spanish origin (Pilo de la Fuente et al., 2011). It
is very likely that its presence in Chile is derived from mi-
grations from Spain, one of the main population contribu-
tors to the current Chilean population. It was shown by Cali
et al. (1991) that the p.Arg395Cys mutation dramatically
reduces enzyme activity. In our study, we provide support
to this observation using bioinformatics tools. According to
our tridimensional protein model, position 395 is located
within the ERR triad, which may act as a folding motif, sta-
bilizing heme binding and redox partner binding (Prosser et
al., 2006). It is predicted that mutation in Cys395 may in-
crease distances and the loosened interactions may favor
misfolding, thus affecting adrenoxin (ADX) binding (Fig-
ure 2B lower panel).
It is worthy of note that the mutation c.Arg395Ser is
located in the same genomic position (penultimate nucleo-
tide of exon 6) as the c.Arg395Cys (codon CGT to TGT;
c.1183C > T) (Chen et al. (1998). Given the special loca-
tion of this mutation in the exon-intron boundary, Chen et
al. (1998) proposed that the c.Arg395Ser mutation may af-
fect normal splicing and gene expression efficiency, imply-
ing that this specific genomic DNA position may also affect
gene expression in other mutations located in the same
genomic site. As far as we know, there are no reports as-
sessing the possible impact of the mutation c.1183C > T on
gene expression or the splicing process. Although we have
not determined whether c.1183C > T affects gene expres-
sion efficiency, we show here that the sequence containing
the c.1183C > T mutation is fully transcribed (Figure 1D).
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Figure 2 - CYP27A1 modeling. A) Tridimensional model of wild type protein CYP27A1 showing HEM group and position of Arg395. B (upper panel):
Enlargement of amino acids region showing that Arg395 interacts with Phe438 by pi-cationic interaction and is also involved in H-bond interactions with
the carboxyl group of Glu392 and the main-chain nitrogen from Pro441. B (lower panel): Mutation to Cys395 will increase distances and the interactions
loosened will favor misfolding, which may affect ADX binding.
Therefore, it is very likely that the sole effect of the amino
acid change generated by the amino acid change
c.Arg395Cys is sufficient to impair enzyme activity and
cause CTX (Cali et al., 1991).
Regarding the c.1185-1G > A mutation found in ho-
mozygous state in patient 2, we also show bioinformatic
and molecular evidence supporting a role in the CYP27A1
splicing process. We show that this mutation causes exon 7
skipping and the generation of a premature stop codon in
exon 8. As a consequence, the protein lacks the two binding
domains for its cofactors adrenodoxin (ADX) and ADX
reductase, as well as relevant residues for HEM coordina-
tion such as Cys476. It is also possible that this patient lacks
the CYP27A1 protein, as the stop codon generated by exon
skipping is located > 55 nucleotides upstream of the most 3’
exon-exon junction, possibly leading the activation of the
Nonsense-Mediated mRNA Decay (NMD) surveillance
pathway (Karam et al., 2013).
It is necessary to emphasize the importance of clinical
and biochemical CTX screening in young patients with
early disease signs, such as neonatal cholestatic jaundice,
childhood diarrhea, and congenital or juvenile bilateral cat-
aracts, given that a treatment with CDCA is available. In
the absence of national screening programs, ophthalmolo-
gical findings in patients with CTX are interesting since
they are one of the first signs of the disease, often before di-
agnosis of CTX is made. It is important to emphasize that
early treatment during childhood and before CNS deposits
appear, may avoid progression of the disease.
In conclusion, we have reported herein the genetic,
molecular and clinical characteristics of two Chilean CTX
cases, showing two novel splice-affecting variants in the
CYP27A1 gene. Since CTX is a treatable disease, we pro-
pose to screen new CTX cases among children with early
disease signs, such as bilateral cataracts, followed by test-
ing their plasma cholestanol levels and searching mutations
in the CYP27A1 gene in the patients who are positive for
biochemical screening.
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